BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 2895504)

  • 41. Role of inflammatory factors in neurodegeneration.
    Członkowska A; Kurkowska-Jastrzebska I; Członkowski A
    Neurol Neurochir Pol; 2001; 35 Suppl 3():13-22. PubMed ID: 12001649
    [No Abstract]   [Full Text] [Related]  

  • 42. Nervous tissue culture--a tool to study uptake and action of neurotransmitters in the human central nervous system.
    Hösli L; Hösli E; Andrès PF
    Int J Neurol; 1979; 13(1-4):67-80. PubMed ID: 45450
    [No Abstract]   [Full Text] [Related]  

  • 43. [Effect of memantine on central neurotransmitter systems. Review of the results].
    Maj J
    Arzneimittelforschung; 1982; 32(10):1256-9. PubMed ID: 6129854
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Experimentally induced parkinsonism.
    Poirier LJ; Sourkes TL
    Res Publ Assoc Res Nerv Ment Dis; 1972; 50():416-33. PubMed ID: 4403656
    [No Abstract]   [Full Text] [Related]  

  • 45. Adenosine receptor antagonists and Parkinson's disease: actions of the A2A receptor in the striatum.
    Richardson PJ; Gubitz AK; Freeman TC; Dixon AK
    Adv Neurol; 1999; 80():111-9. PubMed ID: 10410709
    [No Abstract]   [Full Text] [Related]  

  • 46. [Depression: clinical aspects].
    Mendlewicz
    Arch Belg Med Soc; 1981 Feb; 39(2):96-102. PubMed ID: 6119057
    [No Abstract]   [Full Text] [Related]  

  • 47. Biochemical neuropathology of Parkinson's disease.
    Javoy-Agid F; Ruberg M; Taquet H; Bokobza B; Agid Y; Gaspar P; Berger B; N'Guyen-Legros J; Alvarez C; Gray F
    Adv Neurol; 1984; 40():189-98. PubMed ID: 6695594
    [No Abstract]   [Full Text] [Related]  

  • 48. [Pathogenesis and basis of the therapy of Parkinson's disease].
    van der Drift JH; Stoof JC
    Ned Tijdschr Geneeskd; 1981 Apr; 125(16):620-5. PubMed ID: 6113554
    [No Abstract]   [Full Text] [Related]  

  • 49. Pharmacological challenge strategies: implications for neurochemical mechanisms in affective disorders and treatment approaches.
    Risch SC; Kalin NH; Murphy DL
    J Clin Psychopharmacol; 1981 Jul; 1(4):238-43. PubMed ID: 6117587
    [No Abstract]   [Full Text] [Related]  

  • 50. [Influencing of Parkinson's syndrome via intervention in the dopamine metabolism].
    Korten JJ; van Rossum JM
    Ned Tijdschr Geneeskd; 1973 Feb; 117(8):296-305. PubMed ID: 4350090
    [No Abstract]   [Full Text] [Related]  

  • 51. [Interaction of opiates and opioid peptides with cerebral mediator systems].
    Bulaev VM; Raevskiĭ KS
    Usp Fiziol Nauk; 1982; 13(2):65-92. PubMed ID: 6124068
    [No Abstract]   [Full Text] [Related]  

  • 52. N-methyl-D-aspartate antagonists as drug models of schizophrenia: a surprising link to tobacco smoking.
    Domino EF; Mirzoyan D; Tsukada H
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Aug; 28(5):801-11. PubMed ID: 15363604
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacology of the central nervous system.
    Nelson SR; Walaszek EJ
    Prog Neurol Psychiatry; 1971; 26():123-49. PubMed ID: 4151158
    [No Abstract]   [Full Text] [Related]  

  • 54. Modulation of neurotransmitter systems by dehydroepiandrosterone and dehydroepiandrosterone sulfate: mechanism of action and relevance to psychiatric disorders.
    Pérez-Neri I; Montes S; Ojeda-López C; Ramírez-Bermúdez J; Ríos C
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jul; 32(5):1118-30. PubMed ID: 18280022
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biochemical aspects of schizophrenia.
    Lewis ME
    Essays Neurochem Neuropharmacol; 1980; 4():1-67. PubMed ID: 6104597
    [No Abstract]   [Full Text] [Related]  

  • 56. [The relationship between iron metabolism in central nervous system and Parkinson's disease].
    Wang J; Jiang H; Xie JX
    Sheng Li Ke Xue Jin Zhan; 2003 Jan; 34(1):67-70. PubMed ID: 12778816
    [No Abstract]   [Full Text] [Related]  

  • 57. Central synaptic transmitters.
    Curtis DR
    Proc Aust Assoc Neurol; 1970; 7():55-9. PubMed ID: 4328430
    [No Abstract]   [Full Text] [Related]  

  • 58. [A biochemical theory of schizophrenia].
    Kornhuber HH; Kornhuber J; Kim JS; Kornhuber ME
    Nervenarzt; 1984 Nov; 55(11):602-6. PubMed ID: 6151120
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis.
    Yang AC; Tsai SJ
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28771182
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Biochemical studies of schizophrenia].
    Kakimoto Y
    Nihon Rinsho; 1976 Sep; 34(9):2706-11. PubMed ID: 1033308
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.